The diabetic patient, when type 2 diabetes is newly diagnosed, raises a therapeutic problem commonly observed in clinical practice, which is more complex than expected at first glance. The physician has to select the most appropriate antidiabetic oral agent as first choice, to consider the potential of using combined glucose-lowering therapies, to fix glycaemic target taking into account the individual benefit/risk ratio, and to offer the best protection against cardiovascular complications. The present clinical case illustrates such therapeutic problem describing a patient with a high cardiovascular risk profile who experienced a hypoglycaemic episode after the prescription of glibenclamide following the discovery of a moderate hyperglycaemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hepatitis B vaccine and juvenile idiopathic arthritis: comparison of the seropositivity rates with healthy children at the time of diagnosis and booster dose response under treatment.
Clin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Introduction/objectives: The study aimed to determine whether in children with newly diagnosed juvenile idiopathic arthritis (JIA) hepatitis B surface antibody (anti-HBs) differs from healthy children and to see whether the revaccination is safe and effective under JIA treatment.
Methods: Patients who were followed up with a diagnosis of JIA between January 2020 and February 2024 were included. The control group consisted of healthy children matched for age and gender.
Background: The Bombay and para-Bombay blood groups are rare blood types that are significant to clinical blood transfusions. Accurate para-Bombay blood group identification is important for the safety of transfusions.
Methods: Serological and molecular biology methods were used to detect one case of ABO blood type.
A Machine Learning Model Using Cardiac CT and MRI Data Predicts Cardiovascular Events in Obstructive Coronary Artery Disease.
Radiology
January 2025
From the Department of Cardiology (T.P., K.H., T.G., A.L., E.G., A.U., J.G.D., P.H.), MIRACL.ai (Multimodality Imaging for Research and Analysis Core Laboratory: and Artificial Intelligence) (T.P., S.T., K.H., T.G., A.L., E.G., A.U., J.G.D., P.H.), Inserm MASCOT-UMRS 942 (T.P., K.H., T.A.S., T.G., A.L., E.G., A.U., J.G.D., P.H.), and Department of Radiology (T.P., V.B., L.H., T.G.), Université Paris Cité, University Hospital of Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; Cardiovascular Magnetic Resonance Laboratory (T.P., T.H., T.U., F.S., S.C., P.G., J.G.) and Cardiac Computed Tomography Laboratory (T.P., T.H., T.L., B.C., T.U., F.S., S.C., H.B., A.N., M.A., P.G., J.G.), Hôpital Privé Jacques Cartier, Institut Cardiovasculaire Paris Sud, Ramsay Santé, 6 Avenue du Noyer Lambert, 91300 Massy, France; Scientific Partnerships, Siemens Healthcare France, Saint-Denis, France (S.T.); Department of Cardiology, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Brussels, Belgium (A.U.); and Department of Cardiovascular Imaging, American Hospital of Paris, Neuilly, France (O.V., M.S.).
Background Multimodality imaging is essential for personalized prognostic stratification in suspected coronary artery disease (CAD). Machine learning (ML) methods can help address this complexity by incorporating a broader spectrum of variables. Purpose To investigate the performance of an ML model that uses both stress cardiac MRI and coronary CT angiography (CCTA) data to predict major adverse cardiovascular events (MACE) in patients with newly diagnosed CAD.
View Article and Find Full Text PDFTRIB1 facilitates the proliferation and migration of ovarian cancer cells by inducing EMT progression.
Histol Histopathol
December 2024
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
Aim: Ovarian cancer (OC) is a fatal female malignant tumor that severely impacts the health of women worldwide. Due to the lack of diagnostic biomarkers, 70% of OC patients are considered in the advanced stage at the first diagnosis. Exploring novel biomarkers for OC diagnosis has become an urgent clinical need to address.
View Article and Find Full Text PDFDeficient Mismatch Repair and BRAF Mutations in Metastatic Colorectal Cancer in the South Island of New Zealand.
Asia Pac J Clin Oncol
January 2025
Wellington Blood and Cancer Centre, Health New Zealand/Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington, New Zealand.
Aim: Manatū Hauora, the Ministry of Health of New Zealand (NZ), published minimum standards for molecular testing of colorectal cancers (CRCs) in June 2018. These included mismatch repair (MMR) testing at diagnosis and BRAFV600E mutation analysis on newly diagnosed stage IV CRCs. This study aimed to determine the proportion of patients with CRC in the South Island of NZ with metastatic deficient mismatch repair (dMMR) CRC, the proportion of metastatic CRCs and dMMR CRCs that have a BRAFV600E mutation, and audit testing for BRAF mutations and appropriate referral to genetics services.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!